Prescribing information

 

Access to nurse support to perform first-year monitoring for patients initiated on GILENYA.

During patients' first year of treatment, it is recommended that liver transanimases are monitored at 1, 3, 6, 9 and 12 months and periodically thereafter. The time points may be varied, depending on when your centre chooses to conduct them.

Assessments of complete blood count (CBC) are recommended periodically during treatment, at month 3 and at least yearly thereafter.

GILENYACONNECT offers easy access to dedicated nurse teams, providing a unique service appropriate to the level of support your centre requires and the individual needs of your patients.

 Infographic detailing what the blood tests involve.

We recognise that you may not always need outside assistance for routine checks. With GILENYACONNECT you can choose when to access the services of our specialist nurses according to your requirements.

For more information and details on how to enrol your patients in the GILENYACONNECT programme, please speak to your local Novartis key account manager.

GILENYACONNECT is a healthcare service that is offered as a programme for patients prescribed GILENYA. It is not intended to replace the services of the patient’s NHS medical team.

Gd+: gadolinium enhancing; MRI: magnetic resonance imaging; RES: rapidly evolving severe; RRMS: relapsing remitting multiple sclerosis.

Indication: GILENYA is indicated as a single disease modifying therapy in highly active RRMS for the following groups of adult patients and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with ≥1 disease modifying therapy, or patients with RES RRMS defined by ≥2 disabling relapses in 1 year, and with 1 or more Gd+ lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.1

Reference

  1. GILENYA (fingolimod) Summary of Product Characteristics.
GIL19-C053d March 2020.
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the patient safety information (PSI) tool at https://psi.novartis.com
If you have a question about the product, please contact Medical Information on 01276 692255 or by email at [email protected]